Clinical–Alimentary TractThe Relative Efficacies of Gastroprotective Strategies in Chronic Users of Nonsteroidal Anti-inflammatory Drugs
Section snippets
Description of Data Sets
In Manitoba, the Manitoba Centre for Health Policy maintains a comprehensive health utilization data set called the Population Health Research Data Repository.19, 20 This data set contains health care utilization data on all residents of Manitoba, provided by the provincial department of health. The Population Health Research Data Repository is composed of a number of distinct data sets containing information on patient demographics, all outpatient and hospital visits since April 1984 including
Results
We identified 466,187 adults who had filled at least one NSAID prescription between April 1995 and March 2006. Within this cohort of individuals, we identified 1382 admitted with upper GI complications and 736 with peptic ulcer diseases who had hospital stays exceeding 1 day. The 1382 upper GI complication cases were matched to 33,957 age- and sex-matched controls, each of whom was also using an nsNSAID or COX-2 inhibitor within 14 days of his or her case’s event date.
The baseline
Discussion
Based on our results, use of any of the commonly recommended basic gastroprotective strategies, including nsNSAID + PPI, nsNSAID + low-dose misoprostol, and COX-2 inhibitor alone, was associated with a significant reduction in the risk of developing an overall upper GI complication or upper GI complication secondary to peptic ulcer disease. Among the basic gastroprotective strategies, COX-2 inhibitor alone was numerically superior to nsNSAID + PPI, but the difference was not statistically
References (43)
- et al.
Evidence of aspirin use in both upper and lower gastrointestinal perforation
Gastroenterology
(1997) - et al.
Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs
Lancet
(1994) - et al.
Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs
Lancet
(1994) - et al.
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial
Lancet
(2004) - et al.
Use of pharmaceuticals by inflammatory bowel disease patients: a population-based study
Am J Gastroenterol
(2001) - et al.
The accuracy of diagnosis and procedural codes for patients with upper GI hemorrhage
Gastrointest Endosc
(2000) - et al.
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications
Am J Med
(2005) - et al.
Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial
Gastroenterology
(2004) - et al.
Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs
Gastroenterology
(2007) - et al.
Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers
Clin Ther
(1999)
Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial
Lancet
Chapter 5: Arthritis-related prescription medications
Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugsA meta-analysis
Ann Intern Med
Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons
Ann Intern Med
Trends in management and outcomes of acute nonvariceal upper gastrointestinal bleeding: 1993–2003
Clin Gastroenterol Hepatol
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritisVIGOR Study Group
N Engl J Med
Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugsA randomized, double-blind, placebo-controlled trial
Ann Intern Med
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trialCelecoxib Long-term Arthritis Safety Study
JAMA
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial
N Engl J Med
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention
N Engl J Med
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery
N Engl J Med
Cited by (0)
Supported by grants from the Manitoba Medical Services Foundation, the Health Sciences Centre Foundation (Winnipeg), and the Canadian Institutes of Health Sciences Regional Partnership Program. This study was not funded in any part by private industry. L.T. is the recipient of the University of Manitoba Rudy Falk Clinical Scholar Award and has previously received grant support from Astra-Zeneca Canada, Janssen-Ortho Canada, and Altana Canada.
The results and conclusions are those of the authors, and no official endorsement by Manitoba Health or the Manitoba Centre for Health Policy is intended or should be inferred.
- 1
L.T. has served on advisory panels for Janssen-Ortho Canada and Novartis Canada. The other authors have no financial conflicts of interest to disclose.